Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Meta-Analysis & Public Policy Implications

Andrew T. Levin, Kensington B. Cochran, Seamus P. Walsh
doi: https://doi.org/10.1101/2020.07.23.20160895
Andrew T. Levin
Levin is a professor of economics at Dartmouth College, research associate of the NBER, and international research fellow of the Centre for Economic Policy Research. Cochran and Walsh are recent graduates of Dartmouth College
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: andrew.t.levin@dartmouth.edu
Kensington B. Cochran
Levin is a professor of economics at Dartmouth College, research associate of the NBER, and international research fellow of the Centre for Economic Policy Research. Cochran and Walsh are recent graduates of Dartmouth College
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seamus P. Walsh
Levin is a professor of economics at Dartmouth College, research associate of the NBER, and international research fellow of the Centre for Economic Policy Research. Cochran and Walsh are recent graduates of Dartmouth College
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

This paper assesses the age specificity of the infection fatality rate (IFR) for COVID-19. Our benchmark meta-regression synthesizes the age-specific IFRs from four recent large-scale seroprevalence studies conducted in Belgium, Geneva, Spain, and Sweden. The estimated IFR is close to zero for children and younger adults but rises exponentially with age, reaching about 0.3 percent for ages 50-59, 1 percent for ages 60-69, 4 percent for ages 70-79, and 24 percent for ages 80 and above. We compare those predictions to the age-specific IFRs implied by recent seroprevalence studies of six U.S. geographical areas, three small scale studies, and three countries (Iceland, New Zealand, and Republic of Korea) that have engaged in comprehensive tracking and tracing of COVID-19 infections. We also review more than 30 other seroprevalence studies whose design was not well-suited for estimating age-specific IFRs. Our findings indicate that COVID-19 is not just dangerous for the elderly and infirm but also for healthy middle-aged adults, for whom the fatality rate is roughly 50 times greater than the risk of dying in an automobile accident. Consequently, the overall IFR for a given location is intrinsically linked to the age-specific pattern of infections. In a scenario where the U.S. infection rate reaches nearly 30 percent, our analysis indicates that protecting vulnerable age groups could prevent over 200,000 deaths.

Declaration The authors have no financial interests nor any other conflicts of interest related to this study. No funding was received for conducting this study. The views expressed here are solely those of the authors and do not represent the views of any other person or institution.

Objective Determine age-specific infection fatality rates for COVID-19 to inform public health policies and communications that help protect vulnerable age groups.

Methods Studies of COVID-19 prevalence were collected by conducting an online search of published articles, preprints, and government reports identified by online searches. A total of 48 studies were identified covering a wide array of locations in advanced economies. Studies were screened using four specific criteria: (i) transparency of seroprevalence test characteristics and procedures; (ii) representative sample of the general population; (iii) effective pandemic containment by the time of the study; and (iv) reporting of age-specific prevalence and confidence intervals. Age-specific IFRs were computed using reported fatalities four weeks after the midpoint date of each study, reflecting the typical pattern of lags in fatalities and reporting. Four studies were identified as benchmarks and used in meta-regression of the infection fatality rate (IFR) as a function of age, using the STATA metareg procedure. The meta-regression results were compared with age-specific IFRs for 12 other locations -- an “out-of-sample” exercise that statisticians commonly use in assessing the validity of forecasting models.

Results Our analysis finds a highly significant exponential relationship between age and IFR for COVID-19. The estimated age-specific IFRs are close to zero for children and younger adults but rise to about 0.3 percent for ages 50-59, 1 percent for ages 60-69, 4 percent for ages 70-79, and 24 percent for ages 80 and above. Nearly all of the age-specific IFRs from all 16 studies fall within the 95% prediction interval of the meta-regression.

Discussion Our analysis indicates that the link between IFR and age is far stronger than the link with comorbidities such as chronic pulmonary disease. Other recent studies indicate that other characteristics—including race, ethnicity, and socioeconomic status—are not tightly linked to IFR but are strongly tied to infection rates and hence to disparities in mortality outcomes.

Conclusions Our results clearly indicate that COVID-19 is not just dangerous for the elderly and infirm but also for healthy middle-aged adults, for whom the fatality rate is roughly 50 times greater than the risk of dying in an automobile accident. Furthermore, the overall IFR for COVID-19 should not be viewed as an exogenously fixed parameter but as intrinsically linked to the age-specific pattern of infections. Consequently, individual and collective efforts that minimize infections in older adults could substantially decrease total deaths. In a scenario where the infection rate of the U.S. population reaches nearly 30%, our analysis indicates that protecting vulnerable age groups could prevent over 200,000 deaths.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received for this research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study is a meta-analysis using information from publicly available studies (published articles, Medrxiv preprints, and government reports).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

This study is a meta-analysis using information from published articles, preprints, and government reports; all sources are listed in the bibliography with active URLs. The data and Stata code used in performing the meta-regression analysis are provided as Supplementary Materials.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 24, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Meta-Analysis & Public Policy Implications
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Meta-Analysis & Public Policy Implications
Andrew T. Levin, Kensington B. Cochran, Seamus P. Walsh
medRxiv 2020.07.23.20160895; doi: https://doi.org/10.1101/2020.07.23.20160895
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Meta-Analysis & Public Policy Implications
Andrew T. Levin, Kensington B. Cochran, Seamus P. Walsh
medRxiv 2020.07.23.20160895; doi: https://doi.org/10.1101/2020.07.23.20160895

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (238)
  • Allergy and Immunology (519)
  • Anesthesia (124)
  • Cardiovascular Medicine (1407)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (580)
  • Epidemiology (10264)
  • Forensic Medicine (6)
  • Gastroenterology (526)
  • Genetic and Genomic Medicine (2611)
  • Geriatric Medicine (253)
  • Health Economics (495)
  • Health Informatics (1727)
  • Health Policy (788)
  • Health Systems and Quality Improvement (669)
  • Hematology (266)
  • HIV/AIDS (563)
  • Infectious Diseases (except HIV/AIDS) (12066)
  • Intensive Care and Critical Care Medicine (647)
  • Medical Education (272)
  • Medical Ethics (83)
  • Nephrology (286)
  • Neurology (2448)
  • Nursing (143)
  • Nutrition (374)
  • Obstetrics and Gynecology (486)
  • Occupational and Environmental Health (565)
  • Oncology (1314)
  • Ophthalmology (397)
  • Orthopedics (145)
  • Otolaryngology (235)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (341)
  • Pediatrics (776)
  • Pharmacology and Therapeutics (328)
  • Primary Care Research (294)
  • Psychiatry and Clinical Psychology (2390)
  • Public and Global Health (4987)
  • Radiology and Imaging (892)
  • Rehabilitation Medicine and Physical Therapy (520)
  • Respiratory Medicine (680)
  • Rheumatology (307)
  • Sexual and Reproductive Health (253)
  • Sports Medicine (244)
  • Surgery (296)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)